Vivos Therapeutics (VVOS) to Release Quarterly Earnings on Monday

Vivos Therapeutics (NASDAQ:VVOS) will likely be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $7.0970 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Vivos Therapeutics Price Performance

Shares of NASDAQ:VVOS opened at $1.22 on Monday. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.78 and a current ratio of 0.78. The business’s fifty day moving average price is $1.59 and its two-hundred day moving average price is $2.29. The stock has a market cap of $12.77 million, a PE ratio of -0.69 and a beta of 6.94. Vivos Therapeutics has a one year low of $1.19 and a one year high of $7.95.

Institutional Investors Weigh In On Vivos Therapeutics

Several hedge funds have recently made changes to their positions in VVOS. XTX Topco Ltd purchased a new stake in shares of Vivos Therapeutics in the second quarter valued at $65,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics during the second quarter worth about $220,000. Connective Capital Management LLC acquired a new stake in Vivos Therapeutics in the 3rd quarter worth about $620,000. Finally, DRW Securities LLC grew its holdings in Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares during the period. Institutional investors and hedge funds own 26.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Ascendiant Capital Markets decreased their price objective on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, December 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Finally, Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.92.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.